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follow-up time was 23.4 months (range 10–57 months). 
So far, there has been no signifi cant change in any of the 
determined parameters (end-diastolic diameter, end-
systolic diameter, fractional shortening, EF) over time 
during all follow-up investigations. Mitoxantrone did not 
cause signs of congestive heart failure in any of the pa-
tients. Further cardiac monitoring is, however, needed 
to determine the safety of mitoxantrone after longer fol-
low-up times and at higher cumulative doses. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Previous studies showed that mitoxantrone, an an-
thracenedione with immunosuppressive effects, can re-
duce disability progression and clinical exacerbations in 
patients with multiple sclerosis (MS)  [1–6] . Therefore, 
mitoxantrone is increasingly being used especially for sec-
ondary progressive (SP) MS and repeated courses. De-
spite this promising therapeutic effect, however, there is 
still much concern about the safety of this drug because 
of its potential cardiac side effects, which seem to increase 
with higher cumulative dosages  [6, 7] . The cardiotoxicity 
is most likely caused by the formation of iron chelates, 
which promote formation of reactive oxygen intermedi-
ates that lead to damage of myocardial tissue  [8] . In the 
past, mitoxantrone-induced cardiac side effects were 
mainly observed in cancer patients (e.g. prostate or breast 
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 Abstract 
 Previous studies showed that mitoxantrone can reduce 
disability progression in patients with multiple sclerosis 
(MS). There is, however, concern that it may cause irre-
versible cardiomyopathy with reduced left ventricular 
(LV) ejection fraction (EF) and congestive heart failure. 
The aim of this prospective study was to investigate car-
diac side effects of mitoxantrone by repetitive cardiac 
monitoring in MS patients. The treatment protocol called 
for ten courses of a combined mitoxantrone (10 mg/m 2  
body surface) and methylprednisolone therapy. Before 
each course, a transthoracic echocardiogram was per-
formed to determine the LV end-diastolic diameter, the 
end-systolic diameter and the fractional shortening; the 
LV-EF was calculated. Seventy-three patients participat-
ed (32 males; age 48  8 12 years, range 20–75 years; 25 
with primary progressive, 47 with secondary progres-
sive and 1 with relapsing-remitting MS) who received at 
least four courses of mitoxantrone. Three of the 73 pa-
tients were excluded during the study (2 patients discon-
tinued therapy; 1 patient with a previous history of isch-
emic heart disease developed atrial fi brillation after the 
second course of mitoxantrone). The mean cumulative 
dose of mitoxantrone was 114.0  8 33.8 mg. The mean 
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cancer)  [9–12] , who were treated antineoplastically with 
mitoxantrone. The predominant cardiac side effects were 
an asymptomatic decrease of the left ventricular (LV) 
ejection fraction (EF), irreversible cardiomyopathy and 
congestive heart failure (CHF). However, a potentiation 
of cardiotoxicity might be assumed in cancer patients, 
because mitoxantrone is often given in combination with 
other chemotherapy or radiation. Until now, only a few 
studies have investigated the safety of mitoxantrone when 
used as a single-agent therapy in MS. They were mainly 
based on clinical examination  [13–16] or included only a 
limited number of patients with short follow-up times 
 [17, 18] . In this prospective study, the potential cardio-
toxicity of mitoxantrone in MS patients was evaluated by 
repetitive cardiac monitoring before each treatment 
course. We present here the results of an interim analysis 
after the study had lasted 5 years. 
 Methods 
 Study Population 
 In this prospective study, conducted from 1998 to 2004, pa-
tients with a defi nite MS, initially according to the criteria of Poser 
et al.  [19] and since 2001 according to McDonald et al.  [20] , and 
either a deteriorating primary progressive (PP), SP, or a severe re-
lapsing-remitting (RR) MS were included. On entry into the study, 
the patients underwent a neurological examination and a quantita-
tive assessment of disability using the expanded disability status 
scale (EDSS) of Kurtzke  [21] . Only PP and SP patients who had 
worsened by at least 0.5 or more EDSS points during the preceding 
12 months were enrolled. Before inclusion, all other disease-modi-
fying therapies were discontinued. All patients had given their writ-
ten informed consent to participate in the study. 
 Treatment Protocol 
 The treatment protocol called for ten courses of a combined 
mitoxantrone and methylprednisolone (MP) therapy. The fi rst 
three courses were given at 3-month intervals. Course four was ad-
ministered 4 months after the previous course; course fi ve, 5 months 
after this, and courses six to eight at 6-month intervals after course 
fi ve; courses nine and ten were each administered 1 year after the 
previous course. This means that the entire treatment phase lasted 
nearly 5 years (57 months). During each course MP (500 mg, di-
luted in 500 ml of 0.9% NaCl solution) was intravenously admin-
istered on 5 successive days. On day 3, mitoxantrone in a dose of 
10 mg/m 2  body surface was slowly infused (over at least 1 h) after 
the MP. The antiemetic ondansetron (4 mg) was given 30 min be-
fore mitoxantrone. 
 Patients with contraindications to MP (e.g. gastric ulcer, osteo-
porosis, psychiatric disorders, glaucoma, ongoing infections, severe 
diabetes mellitus, or severe hypertension) received mitoxantrone 
as a single-agent therapy. Those patients who developed severe side 
effects due to MP (e.g. severe hyperglycemia, hypertensive crisis, 
psychosis) during the study were given mitoxantrone without MP 
at the following treatment courses. 
 The white blood cell and platelet counts were determined before 
and 1, 2, and 4 weeks after each treatment. The mitoxantrone dose 
was reduced to 8 mg/m 2  when the white blood cell count fell below 
1,000/  l or the platelet count, below 25,000/  l after the previous 
treatment course. The treatment was postponed when the patient 
presented with signs of infection. 
 Exclusion and Dropout Criteria 
 Criteria for exclusion were defi ned as follows: (1) the patient 
had received a current or previous treatment with mitoxantrone, 
radiation, other cytotoxic drugs, or (2) had contraindications to 
mitoxantrone (e.g. CHF, LV-EF  ! 50%, severe liver and kidney dis-
ease, pregnancy). 
 Criteria for dropout were defi ned as follows: (1) the patient was 
not compliant, i.e. did not appear at follow-up treatment, and 
(2) mitoxantrone caused severe side effects (e.g. serious infections 
after mitoxantrone therapy; signs of CHF, decrease of the LV-EF 
to a value  ! 50% or by 10% or more from baseline; new onset of 
liver or kidney disease, cancer or leukemia  [22] ; allergy to mitoxan-
trone). 
 Cardiac Function Diagnostics 
 The following investigations were performed before each treat-
ment course. A transthoracic echocardiogram was done either in 
the hospital at the Department of Cardiology or in a few cases, out-
side the hospital by a cardiologist. Standard two-dimensional echo-
cardiography using a Toshiba PowerVision 6000 (Toshiba Europe, 
Neuss, Germany) system was applied to evaluate cardiac function. 
LV diameters, i.e. end-diastolic diameter (EDD) and end-systolic 
diameter (ESD), were measured in the parasternal short axis view 
to calculate LV fractional shortening (FS) and LV-EF. LV-EF was 
calculated using the formula derived by Teichholz: LV-EF = {[7/(2,4 
LV-EDD)] LV-EDD 3  – [7/(2,4 LV-ESD)] LV-ESD 3 }/{[7/(2,4 LV-
EDD)] LV-EDD 3 } 2   [23] , which had been shown to allow calculation 
of LV volumes with a very good correlation to volumes derived by 
single-plane angiography  [24] . Grossly asymmetrical LV shapes 
that would limit the value of this formula were not encountered in 
our study population. Regional wall motion abnormalities (hypo-
kinesia, akinesia, dyskinesia) were assessed in a parasternal short 
and long axis and in apical 2- and 4-chamber views. A twelve-lead 
standard ECG was obtained, and the blood pressure was measured 
in each patient before each treatment course. 
 Statistical Analysis 
 A repeated measures ANOVA with two categorical predictors 
(gender and progression), treatment cycles 1–9, and LV-EF, EDD 
and ESD as variables was performed. Post-hoc analysis was done 
using the Bonferroni method to correct for multiple testing (Statis-
tica 6, StatSoft, Tulsa, Okla., USA). 
 Results 
 Seventy-three patients (41 females, 32 males; age 48 
 8 12 years, range 20–75 years) who received at least four 
courses of mitoxantrone therapy were included. Twenty-
fi ve patients had a PP, 47 patients an SP and 1 patient 
an RR form of MS. Three of the 73 patients were exclud-
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ed during the study (2 patients discontinued therapy; 1 
patient with a previous history of ischemic heart disease 
developed atrial fi brillation after the second treatment 
with mitoxantrone). Of the remaining 70 patients, 63 
were given a combined therapy with mitoxantrone and 
MP; 7 patients received only mitoxantrone for the fol-
lowing reasons: 1 patient had suffered from a necrosis of 
the femoral head prior to therapy; 1 patient had a history 
of a gastric ulcer and gastrointestinal bleeding before 
therapy; 1 patient with diabetes mellitus had previously 
developed severe hyperglycemia during treatments with 
MP; 1 patient had a psychosis in his medical history; 2 
patients refused MP treatment; and 1 patient developed 
a transient manic disorder during the second mitoxan-
trone and MP course, and was therefore treated with only 
mitoxantrone at the following courses. The mean follow-
up time was 23.4 months (range 10–57 months). Nine-
teen patients received 8–10 courses, 8 patients 7 courses, 
15 patients 6 courses, 13 patients 5 courses and 15 pa-
tients 4 courses. The mean cumulative dose of mitoxan-
trone was 114.0  8 33.8 mg (range 56.8–190.0 mg). A 
total of 371 echocardiograms was performed. Thirty-six 
echocardiograms were not available for different rea-
sons. 
 At the beginning of the study, the PP-MS group had a 
mean EDSS of 5.2  8 1.3 (range 2.5–7.5) points and the 
SP-MS patients, a mean EDSS of 5.5  8 1.0 (range 3.0–
7.0) points. Our interim analysis after a study period of 
5 years revealed that overall, the EDSS remained almost 
unchanged after four and eight courses in the PP-MS and 
SP-MS groups, respectively. Patients with PP-MS had a 
mean EDSS of 5.2  8 1.5 (range 2.5–7.0) points after four 
courses and 5.1  8 1.4 (range 3.5–6.5) points after eight 
courses. The SP-MS group had a mean EDSS of 5.4  8 
1.1 (3.0–7.0) points after four and 5.6  8 1.5 (range 3.0–
8.0) points after eight courses. 
 Meanwhile, the clinical data on the effects of mitoxan-
trone and MP on the progression of PP-MS and SP-MS 
of a subgroup of these patients have been published 
 [25] . 
 All parameters under investigation (EDD, ESD, FS 
and EF) before courses 1, 4, 6 and 8 are shown in  table 1 . 
Statistical analysis revealed signifi cantly greater values 
for EDD and ESD in males than in females, whereas no 
signifi cant difference was detected for the LV-EF. Over-
all, there was no signifi cant change in any of the echocar-
diographic parameters over the whole treatment period 
[F(14, 224) = 1.175, p = 0.295]. We did not fi nd any gen-
der-specifi c difference in the follow-up of cardiac func-
tion.  Figure 1 shows the LV-EF before therapy and the 
development during the treatment from course one to 
nine in males and females. Similarly, the single analysis 
for each individual patient did not give evidence of dete-
rioration of cardiac function. None of the patients devel-
oped any regional wall motion abnormalities or experi-
enced CHF. 
 Discussion 
 Inclusion Criteria and Study Population 
 Mitoxantrone was shown to have a highly therapeutic 
effect in RR-MS, SP-MS  [1, 26, 27] and acute progressive 
MS  [2] , including mainly young patients with a low EDSS. 
On the basis of these fi ndings, mitoxantrone was ap-
proved by the Food and Drug Administration as a sec-
ond-line treatment (after the failure of immunomodula-
tory therapies) for patients with worsening RR-MS or SP-
n EDD ESD FS EF
Course 1 70 47.585.7 28.284.7 40.584.2 64.785.7
35.0460.0 18.0439.2 30.0447.0 51.0484.0
Course 4 70 46.884.5 27.983.7 40.384.4 64.385.9
38.0455.0 18.0436.0 30.0454.0 51.0484.0
Course 6 42 47.184.3 28.682.9 39.283.8 62.884.7
39.0455.0 22.0435.0 30.0446.0 50.0470.0
Course 8 10 45.583.3 27.184.6 38.384.0 64.088.1
39.0452.0 22.0435.0 30.0444.0 51.0474.0
There was no signifi cant difference over the treatment courses.
 
 Table 1. Mean  8 SD of the EDD, ESD (in 
mm), FS, EF (in %) for the fi rst, fourth, 
sixth and eighth course of mitoxantrone 
treatment 
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MS. We therefore changed the EDSS inclusion criterium 
to at least 0.5 points within the preceding 12 months, 
since we assumed that mitoxantrone might be highly ef-
fective in the early phase of the patient’s disease and in 
those patients with low disability. Our assumption was 
recently supported by the MIMS study  [1, 26] . We de-
cided to also include patients with PP-MS as well as SP-
MS and RR-MS, although there are currently no ap-
proved drugs for the treatment of PP-MS. The effects of 
several immunosuppressive drugs (such as methotrexate, 
azathioprine, or cyclophosphamide), which have been 
tested in progressive MS, are still uncertain and need con-
fi rmation by large controlled studies  [28, 29] . Before we 
started the trial, single PP-MS patients had been treated 
with mitoxantrone in our Department, and it had pre-
vented further progression in most of them. On the basis 
of these observations, we designed the study to compare 
treatment effects of mitoxantrone in patients with PP-MS 
and SP-MS. 
 Treatment Regimen 
 We developed our study design according to that of 
Edan et al.  [2] , who had reported in 1997 on the effective, 
and probably synergistic, combination of mitoxantrone 
and corticosteroids for treatment of MS, and before the 
results of the MIMS study were published in 2002  [1] . 
Edan et al.  [2] showed that a monthly administered, com-
bined mitoxantrone (20 mg) and MP therapy (1 g) over 
6 months was superior to a single-agent MP treatment in 
patients with very active MS. Even now, it is still not 
known to what extent the treatment effects of mitoxan-
trone are sustained after stopping therapy. That is why 
our study included an induction phase, in which mitoxan-
trone was administered every 3 months, and a mainte-
nance phase, in which the intervals between treatment 
were increased. This regimen improves the benefi t/risk 
ratio, in particular for patients with only moderate pro-
gression of the disease, because the potential cumulative 
cardiotoxic side effects of mitoxantrone are reached at a 
late time point during the disease. The treatment protocol 
called for maximally ten courses of mitoxantrone (10 mg/
m 2  body surface), i.e. a total dosage of 100 mg/m 2  body 
surface was not exceeded. Moreover, the cardiotoxicity 
of anthracyclines is related more to the peak of plasma 
concentration than to the total systemic exposure or the 
tissue concentration over time. Thus, in our study mito-
xantrone was administered as a slow infusion (over 1 h). 
 Treatment Effect of Mitoxantrone in PP-MS and 
SP-MS 
 In the SP-MS group, the combination of mitoxantrone 
(10 mg/m 2 ) with MP led to a cessation of the progressive 
disease course in most of our patients or to an improve-
ment in some of them  [25] . This result agrees with the 
data of the multicenter phase III trial  [1] , in which a sig-
nifi cantly greater benefi cial effect was shown in patients 
 Fig. 1. LV-EF during treatment courses one 
to nine in female ( U ) and male ( $ ) pa-
tients. 
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treated with mitoxantrone 12 mg/m 2  compared with 
those who were assigned to mitoxantrone 5 mg/m 2  or 
placebo. In our trial a smaller dosage of mitoxantrone 
(10 mg/m 2 ) had a similarly benefi cial effect. This obser-
vation might prove to be of benefi t to patients undergoing 
long-term treatment with mitoxantrone, because the 
dose-related potential side effects could possibly be re-
duced. In our trial, approximately one-third of all en-
rolled patients suffered from PP-MS. Although PP-MS is 
generally associated with a poorer prognosis than SP-MS, 
our analysis revealed that these patients also benefi t from 
a combined mitoxantrone (10 mg/m 2 ) and MP therapy 
like the patients with SP-MS. However, it must be noted 
that in accordance with the lower incidence of PP-MS, 
the number of PP-MS patients included is still small. 
 Potential Cardiotoxicity of Mitoxantrone 
 This interim analysis showed no signifi cant changes of 
the determined parameters (EDD, ESD, FS, EF) over 
time. Therefore, a mean cumulative dose of about 115 mg 
mitoxantrone (range 56.8–190.1 mg) did not cause a de-
terioration of cardiac function after a mean follow-up 
time of about 2 years (range 10–57 months). None of our 
patients experienced CHF. The only abnormal cardiac 
event observed was the occurrence of atrial fi brillation 
after the second treatment course with mitoxantrone. The 
patient, however, was 75 years old and had a previous 
history of ischemic heart disease and hypertension. This 
might support observations made in earlier studies of a 
higher cardiotoxicity of mitoxantrone in patients with 
concomitant (cardiac) diseases  [9–12] . These studies 
showed that only a minor percentage of all treated pa-
tients, 0.2%  [11] up to 1.1%  [10] , had cardiac side effects. 
The two main risk factors for cardiotoxicity were con-
comitant cardiovascular diseases and a higher cumula-
tive dose of mitoxantrone (besides a combined therapy 
with other chemotherapy or irradiation in cancer pa-
tients). Gender appears to be an additive risk factor, since 
a twofold cardiovascular mortality was found in females 
after coronary artery bypass grafting  [30, 31] . This might 
be dependent on gender-specifi c gene expression  [32] . In 
our study population, mitoxantrone was well tolerated 
and no signs of gender-specifi c effects of mitoxantrone on 
cardiac function were observed. 
 The mean follow-up time in our study was comparable 
to a recent meta-analysis by Ghalie et al.  [33] . In their 
meta-analysis of 1,378 patients, the safety of mitoxan-
trone applied as a single-agent therapy for MS was evalu-
ated from three clinical trials, two of them retrospective 
chart reviews (the MIMS-study by Hartung et al.  [1] ; a 
French study by Edan et al.  [14] , and a German study by 
Mauch et al.  [15, 16] ). Signs of CHF occurred in only 2 
patients, even though 17 of the 779 patients (2.18%) with 
baseline and follow-up evaluation of LV function devel-
oped an asymptomatic deterioration of cardiac function 
with reduction of the LV-EF to  ! 50%. Asymptomatic 
LV-EF reduction tended to be more prevalent when high-
er cumulative doses of  6 100 mg/m 2  mitoxantrone were 
applied, but the difference did not reach signifi cance 
(p = 0.06). Limitations of this meta-analysis were the dif-
ferent treatment regimens and protocols to evaluate LV 
function. Echocardiograms were performed in only 57% 
of all enrolled patients. The intervals between cardiac 
testing were greater than in our study: in the MIMS study 
 [1] echocardiograms were performed before the initia-
tion of therapy and on follow-up at 12, 24 and 36 months; 
in the French multicenter study  [14] , echocardiograms 
were obtained before therapy and after 6, 24 and 60 
months. 
 Overall, the risk of cardiotoxicity due to mitoxantrone 
cannot be ruled out. Especially the long-term safety of 
mitoxantrone needs to be investigated, since Goffette et 
al.  [34] recently reported that three MS patients devel-
oped a delayed CHF 24, 29 and 60 months after receiving 
the last dose of mitoxantrone. However, two of them had 
received cyclophosphamide prior to the mitoxantrone 
therapy; this could be an additional risk factor for a mi-
toxantrone-induced cardiotoxicity. 
 We intend to continue recruiting new patients for our 
ongoing prospective study and to extend the mean follow-
up time to a total of 5 years. 
 Conclusion 
 This interim analysis suggests that repeated evaluation 
of LV function at each successive treatment course with 
mitoxantrone may not be necessary in low-risk patients 
without signs of previous cardiac disease, because the 
probability of cardiotoxicity due to mitoxantrone is very 
low in these patients. However, the inclusion of more pa-
tients and the prolongation of follow-up duration with 
higher cumulative doses of mitoxantrone will be neces-
sary to substantiate this conclusion. 
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